key: cord-0881187-bv5ce54y
authors: Virani, Ahmed; Rabold, Erica; Hanson, Taylor; Haag, Aaron; Elrufay, Rawiya; Cheema, Tariq; Balaan, Marvin; Bhanot, Nitin
title: Guillain-Barré Syndrome associated with SARS-CoV-2 infection
date: 2020-04-18
journal: IDCases
DOI: 10.1016/j.idcr.2020.e00771
sha: 525f1d5d984f50ec3dbb347b66cc1de4d28b4dce
doc_id: 881187
cord_uid: bv5ce54y

Abstract We present a case of Guillain- Barré Syndrome (GBS) in a patient with confirmed COVID-19 infection. GBS in commonly encountered after an antecedent trigger, most commonly an infection. To date, only one case of GBS associated with this infection has been described. Clinicians should consider this entity since it may warrant appropriate isolation precautions especially in a patient who may not present primarily with typical constitutional and respiratory symptoms associated with COVID-19.

First reported in December 2019 as a cluster of pneumonia cases in Wuhan (China), the novel coronavirus (SARS-CoV-2) has been under intense research and investigation. The first known case in the United States was documented in January 2020 in Seattle, Washington [1] . While the J o u r n a l P r e -p r o o f most common symptoms of COVID-19 are fever, cough, and shortness of breath, we present a case in which a SARS-CoV-2 positive patient developed progressive, ascending weakness consistent with Guillain-Barré syndrome (GBS). GBS is a demyelinating disease in which symmetric progressive weakness typically begins distally and moves proximally [2] . In severe cases it can involve respiratory muscles and warrant use of mechanical ventilation [2] . While the world is still grasping at all the complications associated with the initial presentation of COVID-19, we must also realize that a serious neurological sequela may be associated with this viral infection.

A 54-year-old male presented to an outside hospital with complaints of numbness and weakness of his lower extremities of 2-day duration. The weakness progressed to the point that he could not get out of bed and this prompted his family to seek immediate medical attention. In the emergency room, patient also reported having fever, as high as 102F, and a non-productive cough of 10-day duration that did not improve with a short course of oral amoxicillin and steroids that his primary care physician had prescribed. He subsequently developed diarrhea, was diagnosed with Clostridium difficile colitis 2 days ago, and started on treatment that resulted in improvement of symptoms. Vital signs on presentation were remarkable for respiratory rate of 24 breaths per minute with oxygen saturation of 92% on room air, but otherwise stable. Physical exam was most notable for absent lower extremity deep tendon reflexes along with decreased lower extremity strength compared to upper extremities. Complete blood count showed a white blood cell count of 8.6 x10 3 cells/mL, hemoglobin of 15.4g/dL and platelet count of 211 x 10 3 cells/mL with an otherwise normal differential. Procalcitonin was noted to be 0.15 ng/mL and a complete metabolic 

While it was determined to have originated in the China's Hubei province, at the writing of this paper, the SARS-CoV-2 has infected over 1.7 million individuals worldwide with over 100,000 deaths directly attributed to COVID-19 [3] . The virus belongs to the betacoronavirus subgroup of the Coronaviridae family and is comprised of an enveloped single stranded Ribonucleic acid (RNA) genome [4] . Genetic analysis found it to be similar to SARS-CoV and MERS-CoV in its sequence, but different enough to be considered a novel virus [4] . Most immediate causes of death involve acute respiratory distress syndrome (ARDS) and its sequelae along with overwhelming shock from a surge of cytokines [5] . Post viral complications of the infection have not been fully explored at this point.

GBS is an acute areflexic paralytic state that most commonly presents with progressive symmetric weakness, as in our patient. These symptoms generally develop 3 days to 6 weeks following an upper respiratory infection or diarrheal type illness [6] . While the most common infection associated with the development of GBS is campylobacteriosis, viral infections such as cytomegalovirus, Epstein-Barr virus, human immunodeficiency virus and most recently Zika virus have also been associated [6, 7] . The mechanism proposed is an autoimmune reaction where J o u r n a l P r e -p r o o f antibodies to surface glycoproteins are developed on the offending pathogen that also correspond to similar protein structures of peripheral nerve components (molecular mimicry) leading to neurologic involvement [6] . In our patient, the respiratory illness was COVID-19 which we believe to have triggered this neurological process. He was also diagnosed with Clostridium difficile infection 2 days prior to presentation. We are not aware of GBS associated with this infection with this much commonly encountered infection in clinical practice to date. Moreover, the recent report of GBS possibly associated with COVID-19, alluded to below, raises concern for this virus to be a possible trigger.

Previous research has implicated other coronaviruses in neurologic disease. Looking at murine models with infections with the coronavirus, Houtman and Fleming proposed use of an immune compromised mouse model with infection by a coronavirus variant to model human multiple sclerosis, another known demyelinating disease [8, 9] . Evidence has shown spike glycoprotein involvement with murine infection of the neurologic system with support from the hemagglutination proteins, making betacoronavirus a more likely strain of coronavirus to infect neurologic cell lines [10] . In a retrospective study of the MERS-CoV outbreak, one patient was diagnosed with Bickerstaff's encephalitis with overlapping GBS during his treatment course [11] .

Neuromuscular involvement was also reported by Tsai et al in patients infected with the SARS-CoV [12] .

To date, there has been one reported case of GBS associated with SARS-Cov-2 infection in a patient who had returned from Wuhan in January 2020 [13] . That person presented with the classic features of GBS but developed fever and respiratory symptoms subsequently. Her laboratory work up had already revealed lymphopenia and thrombocytopenia on admission though. Hence, there was suggestion of infection, at least based on blood tests on presentation. The 

Tariq Cheema, MD is on the speaker's bureau for Boehringer Ingelheim and Glaxo smith Kline None of the other authors have any potential conflict of interest to disclose

Written informed consent was obtained from the patient for publication of this case report. A copy of the written consent is available for review by the Editor-in Chief of this journal on request.

All the authors have contributed to the writing of the manuscript of the case report. 

First Case of 2019 Novel Coronavirus in the United States

Diagnosis of Guillain-Barré syndrome and validation of Brighton criteria

Coronavirus Cases: Worldometer. (n.d

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality

Guillain-Barré syndrome

Prevalence of Guillain-Barré syndrome among Zika virus infected cases: a systematic review and meta-analysis

Dissociation of demyelination and viral clearance in congenitally immunodeficient mice infected with murine coronavirus JHM

The biology and pathogenesis of coronaviruses

Neuroinvasive and neurotropic human respiratory coronaviruses: potential neurovirulent agents in humans

Neurological Complications during Treatment of Middle East Respiratory Syndrome

Neuromuscular Disorders in Severe Acute Respiratory Syndrome

Guillain-Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence? Lancet Neurol